KALA earnings analysis
What we found in KALA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The available 10-Q extract does not disclose current-period income-statement, segment, balance-sheet, or cash-flow results, so revenue, margin, EPS, and free-cash-flow trends cannot be assessed. The key development is negative control disclosure: management concluded that disclosure controls were ineffective as of June 30, 2026, and the material weakness previously identified in the 2025 Form 10-K remained un-remediated. Remediation activities have begun, while the company reports limited interest-rate sensitivity for its cash equivalents.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Remediation activities initiated
- Management initiated remediation activities for the previously identified material weakness as of June 30, 2026, although the weakness remained un-remediated at that date.
- Limited interest-rate exposure
- The company states that an immediate 10% change in interest rates would not have a material effect on the fair market value of its cash equivalents because of their short-term maturities and fixed-income nature.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ineffective disclosure controls
- Disclosure controls and procedures were concluded to be ineffective at the reasonable-assurance level as of June 30, 2026.
- Unresolved internal-control weakness
- The material weakness identified in the December 31, 2025 Form 10-K remained un-remediated as of June 30, 2026; the company attributes it to insufficient personnel following its restructuring and incomplete key controls over financial reporting.
- Limited operating disclosure
- The filing provides no current-period revenue, margin, EPS, cash-flow, balance-sheet, or segment figures in the available extract, limiting assessment of operating performance as of June 30, 2026.
What they said about what is next.
The provided filing extract contains no quantitative revenue or EPS outlook. Outlook was not provided in the available 10-Q text.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- KALA BIO's Q4 results exhibit a marked recovery in EPS, reporting $0.86 compared to a consensus estimate of -$0.77, leading to a notable EPS surprise of 2.1%. However, revenue remains at $0, indicating continued…
- 10-K · April 15, 2026
- KALA BIO's 2025 Form 10-K describes a strategic pivot from developing its MSC-S biologics program (KPI-012/KPI-014) to evaluating monetization of those assets while building an on‑premises AI research platform…
- 10-Q · November 19, 2025
- KALA BIO reported a Q3 net loss of $7,564,000 (EPS -$1.07), an improvement from Q3 2024 loss of $8,950,000 (EPS -$1.93). Operating expenses declined to $7,239,000 from $9,988,000 a year earlier driven largely by a…
- 10-Q · May 14, 2025
- Kala reported a smaller GAAP net loss of $8,947,000 for the quarter ended March 31, 2025 versus $11,807,000 in the prior-year quarter, driven by lower operating costs and higher grant income; net loss per share improved…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing KALA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever